Skip to main content
SpringerLink
Log in

Sonderformen

  • Chapter
Osteoporose-Manual

  • 106 Accesses

Zusammenfassung

Osteoporose trifft auch Männer — nur 10 bis 15 Jahre später! Betroffen ist nicht nur die Spongiosa, sondern auch die Knochenrinde, mit entsprechend hohem Frakturrisiko.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bailey D (1997) DeThe Saskatchewan pedriatic bone mineral accrual study: bone mineral acquisition during the growing years. Int J Sports Med 18(Suppl3):191–194

    Article  Google Scholar 

  2. Bauer TW, Schils J (1999) DeThe pathology of total joint arthroplasty — I. Mechanisms of implant fixation. Skeletal Radiol 28:423–432

    Article  PubMed  CAS  Google Scholar 

  3. Bauer TW, Schils J (1999) DeThe pathology of total joint arthroplasty — II. Mechanisms of implant failure. Skeletal Radiol 28:483–497

    Article  PubMed  CAS  Google Scholar 

  4. Borderi M, Farneti B, Tampellini L et al. (2002) DeHIV-1, HAART and bone metabolism. New Microbiol 25:375–384

    PubMed  CAS  Google Scholar 

  5. Brumsen C, Hamdy N, Papapoulos S (1997) DeLong-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine 76:266–283

    Article  PubMed  CAS  Google Scholar 

  6. Cohen A, Shane E (2003) DeOsteoporosis after solid organ and bone marrow transplantation. Osteoporos Int 14:617–630

    Article  PubMed  Google Scholar 

  7. Cummings S, Black D, Rubin S (1989) DeLifetime risks of hip, Colles' or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 149:2445–2449

    Article  PubMed  CAS  Google Scholar 

  8. Epstein S, InzerilloA, Caminis J, Zaidi M (2003) DeReview: Disorders associated with acute rapid and severe bone loss. J Bone Miner Res 18:2083–2094

    Article  PubMed  Google Scholar 

  9. El-Shinnawi U, El-Tantawy S (2003) DeThe effect of alendronate sodium on alveolar bone loss in periodontitis (clinical trial). J Int Acad Periodontol 5:5–10

    PubMed  Google Scholar 

  10. Emkey R, Delmas P, Goemaere S et al. (2003) DeChanges in bone mineral density following discontinuation of alendronate therapy of glucocorticoid-treated patients: a retrospective, observational study. Arthritis Rheum 48:1102–1108

    Article  PubMed  CAS  Google Scholar 

  11. Finkelstein J, Hayes A, Hunzelman J et al. (2003) DeThe effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216–1226

    Article  PubMed  CAS  Google Scholar 

  12. Follin S, Black J, McDermott M (2003) DeLack of diagnosis and treatment of osteoporosis in men and women after hip fracture. Pharmacotherapy 23:190–198

    Article  PubMed  Google Scholar 

  13. Frank G (2003) DeRole of estrogen and androgen in pubertal skeletal physiology. Med Pediatr Oncol 41:217–221

    Article  PubMed  Google Scholar 

  14. Gandrud L, Cheung J, Daniels M, Bachrach L (2003) DeLow-dose intravenous pamidronate reduces fractures in childhood osteoporosis. Pediatr Endocrinol Metab 16:887–892

    CAS  Google Scholar 

  15. Glorieux F, Bishop N, Plotkin H et al. (1998) DeCyclical administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947–952

    Article  PubMed  CAS  Google Scholar 

  16. Glowacki J, Hurwitz S, Thornhill T et al. (2003) DeOsteoporosis and vitamin-D deficiency among postmenopausal women with osteoarthritis undergoing total hip arthroplasty. J Bone Joint Surg Am. 85A:2371–2377

    Google Scholar 

  17. Goodship A, Lawes T, Green J. et al. (1999) DeBisphosphonates can inhibit mechanically related loosening of hip prostheses. J Bone Joint Surg (Br) 81-B: Supp III

    Google Scholar 

  18. Gourlay M, Richy F, Reginster J (2003) DeStrategies for the prevention of hip fractures. Am J Med 115:309–317

    Article  PubMed  Google Scholar 

  19. Gruen T, McNeice G, Amstutz H (1979) De„Modes of failure“ of cemented stem-type femoral components: a radiographic analysis of loosening. Clin Orthop 141:17–27

    PubMed  Google Scholar 

  20. Haentjens P, Autier P, Collins J et al. (2003) DeColles fracture, spine fracture, and subsequent risk of hip fracture in men and women. J Bone Joint Surg 85A:1936–1943

    Google Scholar 

  21. Harper K, Weber T (1998) DeSecondary osteoporosis. Diagnostic considerations. Endocrinol Metab Clin North Am 27:325–348

    Article  PubMed  CAS  Google Scholar 

  22. Hartman C, Hochberg Z, Shamir R (2003) DeOsteoporosis in pediatrics. IMAJ 5:509–515

    PubMed  Google Scholar 

  23. Hennings TH (2000) DeProphylaxe des periprothetischen Knochenschwundes durch frühen postoperativen Einsatz von Alendronat — Randomisierte, prospektive, kontrollierte 12-Monate follow-up Studie. Osteologie 9:(Suppl1):75

    Google Scholar 

  24. Hilding M, Ryd L, Toksvig-Larsen S, Aspenberg P (2000) DeClodronate prevents prosthetic migration: a randomized radiostereometric study of 50 total knee patients. Acta Orthop Scand 71:553–557

    Article  PubMed  CAS  Google Scholar 

  25. Hofman S (1999) DeBone marrow oedema in transient osteoporosis, reflex sympathetic dystrophy and osteonecrosis. EFORT 4:138–151

    Google Scholar 

  26. Iwase M, Kim KJ, Kobayashi et al. (2002) DeA novel bisphosphonate inhibits inflammatory bone resorption in a rat osteolysis model with continuous infusioof polyethylene particles. J Orthop Res 20:499–505

    Article  PubMed  CAS  Google Scholar 

  27. Katzman D (2003) DeOsteoporosis in anorexia nervosa: a brittle future? Curr Drug Target CNS Neurol Disord 2:11–15

    Article  CAS  Google Scholar 

  28. Kerner J, Huiskes R, van Lenthe GH et al. (1999) DeCorrelation between pre-operative periprosthetic bone density and post-operative bone loss in THA can be explained by strain-adaptive remodelling. J Biomech 32:695–703

    Article  PubMed  CAS  Google Scholar 

  29. Key L, Ries W, Madyastha P, Reed F (2003) DeJuvenile osteoporosis: recognizing the risk. J Pediatr Endocrinol Metab 16(Suppl3):683–686

    PubMed  Google Scholar 

  30. Köck F, Borisch N, Koester B, Grifka J (2003) DeDas komplexe regionale Schmerzsyndrom Typ I (CRPS I): Ursachen, Diagnostik und Therapie. Orthopäde 32:418–431

    Article  PubMed  Google Scholar 

  31. Kudlacek S, Freudenthaler 0, Weissboeck H et al. (2003) DeLactose intolerance: a risk factor for reduced bone mineral density and vertebral fractures? J Gastroenterol 37:1014–1019

    Article  Google Scholar 

  32. Levy P, Levy E, Audran M et al. (2002) DeThe cost of osteoporosis in men: the French situation. Bone 30:631–636

    Article  PubMed  CAS  Google Scholar 

  33. Mandelin J, Li T-F, Liljeström M et al. (2003) DeImbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. J Bone Joint Surg 85-B:1196–1201

    Article  Google Scholar 

  34. Marcus R, Wong M, Heath H et al. (2002) DeAntiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocrine Reviews 23:16–37

    Article  PubMed  CAS  Google Scholar 

  35. Melton III J, Rajkumar V, Khosla S et al. (2004) DeFracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res 19:25–30

    Article  PubMed  Google Scholar 

  36. Mukherjee A, Shalet S (2003) DeGrowth hormone replacement therapy (GHRT) in children and adolescents: skeletal impact. Med Pediatr Oncol 41:235–242

    Article  PubMed  Google Scholar 

  37. Nakashima A, Yorioka N, Tanji C et al. (2003) DeBone mineral density may be related to atherosclerosis in hemodialysis patients. Osteoporos. Int 14:369–373

    CAS  Google Scholar 

  38. Orwoll E, Ettinger M, Weiss S et al. (2000) DeAlendronate for the treatment of osteoporosis in men. N Engl J Med 343:604–610

    Article  PubMed  CAS  Google Scholar 

  39. Perese E, Perese K (2003) DeHealth problems of women with severe mental illness. J Am Acad Nurse Pract 15:212–219

    Article  PubMed  Google Scholar 

  40. Rauch F, Plotkin H, Zeitlin L, Glorieux F (2003) DeBone mass, size and density in children and adolescence with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 18:610–614

    Article  PubMed  CAS  Google Scholar 

  41. Rehman O, Lane N (2003) DeEffect of glucocorticoids on bone density. Med Pediatr Oncol 41:212–216

    Article  PubMed  Google Scholar 

  42. Reid R (2003) DeBisphosphonates: new indications and methods of administration. Curr Opin Rheumatol 15:458–463

    Article  PubMed  CAS  Google Scholar 

  43. Richy F, Bousquet J, Eherlich G et al. (2003) DeInhaled corticosteroid effects on bone in asthmatic and COPD patients: a quantitative systematic study. Osteoporos Int 14:179–190

    PubMed  CAS  Google Scholar 

  44. Ringe J, Dorst A, Faber H et al. (2003) DeThree-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. Rheumatology 42: 743–749

    Article  PubMed  CAS  Google Scholar 

  45. Ringe J, Faber H, Dorst A (2001) DeAlendronate treatment of established primary osteoporosis in men: results of a 3-year prospective study. J Clin Endocrinol Metab 86:5252–5255

    Article  PubMed  CAS  Google Scholar 

  46. Saag K, Emkey R, Schnitzer T et al. (1998) DeAlendronate for the treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292–299

    Article  PubMed  CAS  Google Scholar 

  47. Santini D, Vespasiani G, Vincenti B (2003) DeThe antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 14:1468–1476

    Article  PubMed  CAS  Google Scholar 

  48. Schwartz A, Sellmeyer D, Ensrud K et al. (2001) DeOlder women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 86:32–38

    Article  PubMed  CAS  Google Scholar 

  49. Scrammel B (1999) DeAlendronate prevents periprosthetic bone loss — 2 year results. J Bone Mineral Res 14(Suppl1):341

    Google Scholar 

  50. Sherman P (2003) DeOsteoporosis and young women. Curr Opin Orthop 14:440–444

    Article  Google Scholar 

  51. Siebler T, Shalet S, Robson H. (2002) DeEffects of chemotherapy on bone metabolism and skeletal growth. Horm Res 58(Suppl1) 180–85

    Google Scholar 

  52. Siminoski K, Fitzgerals A, Flesch G et al. (2000) DeIntravenous pamidronate for treatment of reflex sympathetic dystrophy during breast feeding. J Bone Miner Res 15:2052–2055

    Article  PubMed  CAS  Google Scholar 

  53. Smith I, Dowsett M (2003) DeAromatase inhibitors in breast cancer. N Engl J Med 348:2431–2442

    Article  PubMed  CAS  Google Scholar 

  54. Sudeck P (1902) DeÜber die akute (trophoneurotoxische) Knochenatrophie nach Entzündungen und Traumen der Extremitäten. Deutsch Med Wochenschr 28:336–342

    Article  Google Scholar 

  55. Szulc P, Delmas P (2001) DeBiochemical markers of bone turnover in men. Calcif Tissue Int 69:229–230

    Article  PubMed  CAS  Google Scholar 

  56. Taguchi A, Sanada M, Krall E et al. (2003) DeRelationship between dental panoramic radiographic findings and biochemical markers of bone turnover. J Bone Miner Res 18:1689–1694

    Article  PubMed  Google Scholar 

  57. Van Staa T, Leufkens H, Cooper C (2002) DeThe epidemiology of corticosteroidinduced osteoporosis: a meta-analysis. Osteoporos Int 13:777–787

    Article  PubMed  Google Scholar 

  58. Verrotti A, Greco R Latini G et al. (2002) DeIncreased bone turnover in prepubertal, pubertal and postpubertal patients receiving carbamazepine. Epilepsia 43:1488–1492

    Article  PubMed  CAS  Google Scholar 

  59. Wallach S, Cohen S, Reid D et al. (2000) DeEffects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277–285

    Article  PubMed  CAS  Google Scholar 

  60. Watts N, Harris S, Genant H et al. (1990) DeIntermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73–79

    Article  PubMed  CAS  Google Scholar 

  61. Weber T, Drezner M (2001) DeEffect of alendronate on bone mineral density in male idiopathic osteoporosis. Metabolism 50:912–915

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik III, Klinikum Großhadern, Universität München, Deutschland

    Prof. Dr. Med. Reiner Bartl (Leiter des Bayerischen Osteoporosezentrums)

  2. Abteilung für Unfall-, Handund Wiederherstellungschirurgie, Deutschland

    Dr. Med. Christoph Bartl

Authors
  1. Prof. Dr. Med. Reiner Bartl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. Med. Christoph Bartl
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Bartl, R., Bartl, C. (2004). Sonderformen. In: Osteoporose-Manual. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18792-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18792-6_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-20892-1

  • Online ISBN: 978-3-642-18792-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation